Search

Your search keyword '"Zhang, Yangting"' showing total 2 results
Start Over Author "Zhang, Yangting" Topic 5-methylcytosine
2 results on '"Zhang, Yangting"'

1. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.

Author

Chen L, Shen Q, Xu S, Yu H, Pei S, Zhang Y, He X, Wang Q, and Li D

Subjects
5-Methylcytosine metabolism, Aged, Alzheimer Disease genetics, Alzheimer Disease pathology, Biomarkers metabolism, Case-Control Studies, DNA, Neoplasm metabolism, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, 5-Methylcytosine analogs & derivatives, Alzheimer Disease diagnosis, Cell-Free Nucleic Acids metabolism, DNA Methylation, Epigenesis, Genetic
Abstract

Background: 5-Hydroxymethylcytosine (5hmC) is an epigenetic DNA modification that is highly abundant in central nervous system. It has been reported that DNA 5hmC dysregulation play a critical role in Alzheimer's disease (AD) pathology. Changes in 5hmC signatures can be detected in circulating cell-free DNA (cfDNA), which has shown potential as a non-invasive liquid biopsy material., Objective: However, the genome-wide profiling of 5hmC in cfDNA and its potential for the diagnosis of AD has not been reported to date., Methods: We carried out a case-control study and used a genome-wide chemical capture followed by high-throughput sequencing to detect the genome-wide profiles of 5hmC in human cfDNA and identified differentially hydroxymethylated regions (DhMRs) in late-onset AD patients and the control., Results: We discovered significant differences of 5hmC enrichment in gene bodies which were linked to multiple AD pathogenesis-associated signaling pathways in AD patients compared with cognitively normal controls, indicating they can be well distinguished from normal controls by DhMRs in cfDNA. Specially, we identified 7 distinct genes (RABEP1, CPNE4, DNAJC15, REEP3, ROR1, CAMK1D, and RBFOX1) with predicting diagnostic potential based on their significant correlations with MMSE and MoCA scores of subjects., Conclusion: The present results suggest that 5hmC markers derived from plasma cfDNA can served as an effective, minimally invasive biomarkers for clinical auxiliary diagnosis of late-onset AD.

Published
2022
Full Text
View/download PDF

2. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer’s Disease

Author

Duo Li, Shunliang Xu, Zhang Yangting, Lei Chen, Shengjie Pei, QiuZhen Wang, Xin He, Qianqian Shen, and Hongzhuan Yu

Subjects
Male, Late onset, Disease, Epigenesis, Genetic, chemistry.chemical_compound, Alzheimer Disease, Humans, Medicine, Diagnostic biomarker, Aged, 5-Hydroxymethylcytosine, business.industry, General Neuroscience, High-Throughput Nucleotide Sequencing, DNA, Neoplasm, General Medicine, DNA Methylation, Middle Aged, Circulating Cell-Free DNA, Psychiatry and Mental health, Clinical Psychology, chemistry, Case-Control Studies, 5-Methylcytosine, Cancer research, Female, Geriatrics and Gerontology, business, Cell-Free Nucleic Acids, Biomarkers
Abstract

Background: 5-Hydroxymethylcytosine (5hmC) is an epigenetic DNA modification that is highly abundant in nervous system. It has been reported that 5hmC is significant associated with Alzheimer’s disease (AD). Changes in 5hmC signatures can be detected in circulating cell-free DNA (cfDNA), which has shown potential as a non-invasive liquid biopsy material. However, there is no research about genome-wide profiling of 5hmC in cfDNA and its potential for the diagnosis of AD to date. Methods: We carried out a case-control study and used a highly sensitive and selective high-throughput sequencing of chemical labels to detect the genome-wide profiles of 5hmC in human cfDNA and identified differentially hydroxymethylated regions (DhMRs) in AD patients and the control. Results: We detected a significant difference of 5hmC enrichment in gene bodies which were linked to multiple AD pathogenesis-associated signaling pathways in AD patients compared with cognitively normal controls. AD patients can be well distinguished from cognitively normal controls by differentially hydroxymethylated regions (DhMRs) in cfDNA. Specially, we found 7 distinct genes (RABEP1, CPNE4, DNAJC15, REEP3, ROR1, CAMK1D, and RBFOX1) had prediction diagnostic potential based on their significant correlations with MMSE and MoCA scores. Conclusions: The present results suggest that 5hmC markers derived from plasma cfDNA can be served as an effective, minimally invasive biomarkers for clinical auxiliary diagnosis of late-onset AD. Trial registration: Chinese Clinical Trial Registry, ChiCTR2100042537, registered 13 January 2021-retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=120582.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results